CTLA4 and melanoma: Monoclonal antibodies against the immune checkpoints cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) (ipilimumab) and programmed-death-1 (PD-1) (nivolumab, pembrolizumab) have the potential to induce long-term durable responses in patients with advanced melanoma [1–4].